Navigation Links
Amgen To Present At The Cowen and Company 33rd Annual Health Care Conference
Date:3/1/2013

THOUSAND OAKS, Calif., March 1, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Cowen and Company 33rd Annual  Health Care Conference on Wednesday, March 6, 2013, at the Boston Marriott Copley Place, Boston, Mass., beginning at 9:20 a.m. EST. Arvind Sood , vice president of Investor Relations at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.

(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss , 805-313-6151 (media)
Eric Hyllengren , 805-447-1060 (investors)

 


'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... -- RK Logistics Group, Inc. was awarded California ... Fremont, CA headquarters facility where it provides ... San Jose for hi-tech, pharmaceutical and biomedical ... with its Fremont Innovation District, is excited to strategically partner ... to the hundreds of biotech, pharma and biomed companies throughout ...
(Date:7/11/2017)... has awarded grants totaling more than $2 million to 16 ... Hemophilia Awards Program (BHAP). Four U.S. clinicians and researchers from ... Uniformed Services University of the Health Sciences in ... announced last night during a reception at the International Society ... Germany . ...
(Date:7/10/2017)... CLEVELAND , July 10, 2017  US medical ... billion in 2021, according to Medical Equipment ... released by Freedonia Focus Reports. Continued increases in demand ... the aging of the population and supported by gains ... associated equipment and supplies. New product introductions will also ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... ... “Lucky the Buffalo and Her Adventures”: a collection of heartwarming children’s stories. “Lucky the ... Bieniek Jr. was born in Toledo, Ohio. He attended Woodward High School. He ... married to a brilliant woman with a caring heart named Tiina, who is a hospice ...
(Date:7/18/2017)... ... July 18, 2017 , ... ... and commercialization, has just announced two more sessions of its “From the Helm” ... risk management activities. Led by David Cronin, Cognition’s CEO, the half-hour public webinars ...
(Date:7/18/2017)... ... 18, 2017 , ... The results of an international clinical trial, led in part by a ... type of muscular dystrophy holds promise for a subgroup of patients. , In a paper ... colleagues at 53 study sites in 18 countries describe the clinical benefit of using the ...
(Date:7/18/2017)... , ... July 18, 2017 , ... An inventor from ... sweating. "Due to menopause, I have frequent hot flashes, and I suffer from anxiety ... inconspicuous way to keep cool while out and about." INSTA-FAN meets that need. , ...
(Date:7/18/2017)... (PRWEB) , ... July 18, 2017 , ... Heritage Woods ... from 11 a.m. to 12:30 p.m. on Aug. 15. , The community, which is ... including those on Medicaid, who need some help to maintain their independence. , The ...
Breaking Medicine News(10 mins):